arrow
K

Kjersti Flatmark

Institute of Clinical Medicine
H指数:39
被引数:6,287

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer – A Post Hoc Analysis of METIMMOX Trial Data

癌胚抗原flare在奥沙利铂为基础的化疗下预测微卫星稳定型转移性结直肠癌中尼鲁单抗的获益——METIMMOX试验数据的回顾性分析

2026-05-140
OAAI
Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors

泛癌种唾液酸Tn靶向扩展了CAR疗法在实体瘤中的应用

2025-09-080
OAAI
Enrichment of Cancer-Associated Fibroblasts, Macrophages, and Up-Regulated TNF-α Signaling in the Tumor Microenvironment of CMS4 Colorectal Peritoneal Metastasis

CMS4结肠癌腹膜转移肿瘤微环境中癌症相关成纤维细胞、巨噬细胞和上调的TNF-α信号的富集

2024-12-300
OA
Tumor mutational burden (TMB), BRAF status, and C-reactive protein (CRP) predict response to first-line alternating oxaliplatin-based chemotherapy and nivolumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC)

肿瘤突变负荷(TMB)、BRAF状态和C反应蛋白(CRP)可预测微卫星稳定(MSS)结直肠癌(CRC)患者对一线奥沙利铂为基础化疗联合纳武利尤单抗的应答。

2024-09-010
PRE
Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy and Liver Resection is a Treatment Option for Patients With Peritoneal and Liver Metastases From Colorectal Cancer

细胞减灭术联合腹腔热化疗和肝切除术是结直肠癌腹膜和肝转移患者的治疗选择

2024-08-260
OAAI
Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade

转移性微卫星稳定的BRAF V600E结直肠癌对基于奥沙利铂的一线化疗和免疫检查点阻断的完全反应

2024-06-280
OA
Predictive value of tumor mutational burden (TMB) in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC) given first-line oxaliplatinbased chemotherapy and immune checkpoint blockade (ICB)
2024-03-220
PRE